sorafenib has been researched along with Chronic Disease in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Chen, SZ; Cheng, Z; Cong, WM; Ding, J; Lee, TKW; Li, XF; Lu, XY; Ning, BF; Qu, L; Shen, WF; Sun, W; Wang, HY; Wen, W; Xia, MY; Xiang, DM; Yang, W; Zhou, TF | 1 |
| Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D | 1 |
| Charbit, D; Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Sabourin, JC | 1 |
| Moretti, L; Salemi, S; Scapozza, L; Schmid, I; Simon, D; Simon, HU; Yousefi, S | 1 |
| Beullens, E; Cools, J; Lierman, E; Marynen, P; Michaux, L; Pierre, P; Vandenberghe, P | 1 |
| Bruera, G; Giordano, AV; Lapecorella, M; Lucchesi, A; Mariani, G; Napolitano, M; Ricevuto, E; Tudini, M | 1 |
| Crea, F; Landolfi, R; Leo, A; Miele, L; Pompili, M; Porto, I | 1 |
| Beck-Peccoz, P; Fugazzola, L; Iavarone, M; Perrino, M; Viganò, M | 1 |
| Cross, NC; Erben, P; Hochhaus, A; Hofmann, WK; Klippstein, T; Martin, H; Metzgeroth, G; Mousset, S; Reiter, A; Teichmann, M; Walz, C | 1 |
9 other study(ies) available for sorafenib and Chronic Disease
| Article | Year |
|---|---|
Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.
Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Cell Self Renewal; Cell Transformation, Neoplastic; Chromosomal Instability; Chronic Disease; Female; Humans; Inflammation; Interleukin-6; Keratin-19; Liver; Liver Neoplasms; Macrophages; Male; Mice; Middle Aged; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Rats, Wistar; Sorafenib; src-Family Kinases; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha | 2017 |
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured | 2013 |
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chronic Disease; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2015 |
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Topics: Amino Acid Sequence; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2009 |
FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Topics: Aged; Animals; Benzenesulfonates; Blast Crisis; Blotting, Western; Cells, Cultured; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Male; Mice; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Phosphorylation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Sorafenib | 2009 |
Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Factor VIII; Hemophilia A; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
A case of variant angina in a patient under chronic treatment with sorafenib.
Topics: Angina Pectoris, Variant; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiac Catheterization; Chronic Disease; Coronary Angiography; Electrocardiography; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors | 2010 |
Sorafenib-induced destructive thyroiditis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Hepatitis B, Chronic; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Propranolol; Protein Kinase Inhibitors; Pyridines; Sorafenib; Technetium; Thyroiditis | 2010 |
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2012 |